骨肉瘤患者血清中miR-34a、miR-449a表达及与新辅助化疗耐药的关系  

Expression of Serum miR-34a and miR-449a in Osteosarcoma Patients and Its Relationship with Neoadjuvant Chemotherapy Resistance

作　　者：楚利涛[1] 李兴华[1] 朱梁豫[1] 辛晓林[1] 魏瑄[1] 骆晓飞[1] CHU Litao;LI Xinghua;ZHU Liangyu(Zhengzhou Orthopedic Hospital,Zhengzhou,450005)

机构地区：[1]郑州市骨科医院,450005

出　　处：《实用癌症杂志》2022年第3期388-391,共4页The Practical Journal of Cancer

基　　金：河南省科技攻关项目(编号:182102310183)。

摘　　要：目的分析骨肉瘤患者血清中miR-34a、miR-449a表达水平及与新辅助化疗耐药的关系。方法随机选择骨肉瘤83例,将其纳入研究组。另选取同期体检健康受试者83例,将其纳入对照组。检测血清miR-34a、miR-449a表达水平。问卷调查骨肉瘤患者临床病理特征,给予新辅助化疗,统计耐药情况。结果研究组患者血清miR-34a水平(6.47±1.28)明显高于对照组(P<0.05),miR-449a水平(29.47±1.23)低于对照组(P<0.05)。不同年龄、性别、肿瘤位置患者血清miR-34a、miR-449a水平差异比较无统计学意义(P>0.05)。不同肿瘤大小、临床分期患者的血清miR-34a、miR-449a水平差异比较有统计学意义(P<0.05)。化疗有效组患者血清miR-34a表达水平(7.09±1.09)明显低于无效组(P<0.05),miR-449a表达水平(33.74±2.06)明显高于化疗无效组(P<0.05)。结论骨肉瘤患者血清miR-34a高表达,miR-449a低表达,且表达水平影响新辅助化疗效果,高表达会增加耐药性,增加化疗无效风险。Objective To investigate the expression of serum miR-34a and miR-449a in osteosarcoma patients and its relationship with neoadjuvant chemotherapy resistance.Methods 83 patients with osteosarcoma were the study group,and 83 healthy patients were the control group.Serum miR-34a and miR-449a levels were detected,and the clinical characteristics of patients were collected using questionnaire.All patients received neoadjuvant chemotherapy,and the drug resistance rate was recorded.Results Serum miR-34a level was(6.47±1.28)in the study group,which was significantly higher than that of the control group(P<0.05);meantime,serum miR-449a level was(29.47±1.23)in the study group,which was significantly lower than that of the control group(P<0.05).Serum miR-34a and miR-449a levels showed no significant difference among patients of different age,gender and tumor location(P>0.05),while had statistical difference in patients of different tumor size and clinical stages(P<0.05).The expression level of miR-34a was(7.09±1.09)in chemotherapy effective group,which was significantly lower than that in chemotherapy ineffective group(P<0.05);miR-449a expression level was(33.74±2.06)in chemotherapy effectively group,and was significantly higher than that in chemotherapy ineffective group(P<0.05).Conclusion Patients with osteosarcoma have elevated miR-34a expression and decreased miR-449a expression,and both indicators have impacts on neoadjuvant chemotherapy,furthermore,their elevated expression levels may increase drug resistance and the risk of ineffective chemotherapy.

关 键 词：骨肉瘤 MIR-34A miR-449a 新辅助化疗 关系 表达 

分 类 号：R738.1[医药卫生—肿瘤]